Massachusetts Wealth Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-2,550
Closed -$219K 91
2024
Q4
$219K Sell
2,550
-600
-19% -$64.9K 0.14% 89
2024
Q3
$375K Sell
3,150
-25
-0.8% -$3.33K 0.24% 78
2024
Q2
$453K Hold
3,175
0.3% 75
2024
Q1
$408K Buy
3,175
+500
+19% +$59.5K 0.29% 77
2023
Q4
$277K Buy
+2,675
New +$265K 0.22% 83

Other funds holding NVO

Massachusetts Wealth Management's NVO Position: Q1 2025 in Review

Massachusetts Wealth Management sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 2,550 shares — an estimated $219K sold.

Massachusetts Wealth Management first reported a position in NVO in Q4 2023 and held it in 5 quarters. The position peaked at $453K in Q2 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

  • Massachusetts Wealth Management reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
  • Massachusetts Wealth Management sold 2,550 Novo Nordisk shares in Q1 2025, an estimated $219K.
  • Massachusetts Wealth Management first reported a position in Novo Nordisk in Q4 2023 and held it in 5 quarters.
  • Massachusetts Wealth Management's Novo Nordisk position peaked at $453K in Q2 2024.
  • 1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on Massachusetts Wealth Management's 13F filing for Q1 2025, filed 17 Apr 2025.